We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
101
Milestone Pharmaceuticals
MIST
$127M
– –
-266,667
Closed -$4.97M
AIXC
102
AIxCrypto Holdings Inc
AIXC
$14.2M
– –
-22
Closed -$87K
XBIT icon
103
XBiotech
XBIT
$68.9M
– –
-521,327
Closed -$5.45M
CBAY
104
DELISTED
Cymabay Therapeutics
CBAY
– –
-5,707,411
Closed -$29.2M
ACOR
105
DELISTED
Acorda Therapeutics
ACOR
– –
-18,605
Closed -$6.41M
SRRA
106
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-50,000
Closed -$781K
XLRN
107
DELISTED
Acceleron Pharma
XLRN
– –
-83,900
Closed -$3.31M
FTSV
108
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-250,000
Closed -$1.6M
FOMX
109
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-498,189
Closed -$1.51M
DERM
110
DELISTED
Dermira, Inc.
DERM
– –
-906,943
Closed -$5.79M
ACHN
111
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,095,359
Closed -$3.94M
ONCE
112
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-751,927
Closed -$72.9M
DOVA
113
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-102,205
Closed -$2.86M
GHDX
114
DELISTED
Genomic Health, Inc.
GHDX
– –
-9,244,665
Closed -$627M
LJPC
115
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-1,559,231
Closed -$13.7M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Baker Bros. Advisors held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Baker Bros. Advisors added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Baker Bros. Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Baker Bros. Advisors fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 18 in Q4 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.